Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANGIODYNAMICS INC Director's Dealing 2022

Jul 22, 2022

32939_dirs_2022-07-22_629838a6-ce5c-4019-9945-847cae0b5d8b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2022-07-20

Reporting Person: Trowbridge Stephen A (EVP and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-07-20 Common Stock A 7961 Acquired 88498 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-07-20 Performance Right $ A 15922 Acquired Common Stock (15922) Direct
2022-07-20 Non-Qualified Stock Option (right to buy) $21.53 A 18650 Acquired 2032-07-20 Common Stock (18650) Direct

Footnotes

F1: The acquisition of 7,961 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,961 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

F2: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.